This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

Neil Brewis, Ph.D.
Chief Scientific Officer at F-star Therapeutics


Neil Brewis has 20 years’ experience in antibody engineering and drug discovery and has successfully advanced novel platforms from inception to clinical proof of concept. He is CSO at F-star Therapeutics which is advancing multiple clinical-stage bispecific antibodies for the treatment of patients with cancer, and in particularly those who have resistance to other immuno-oncology medicines.

As Head of Biopharmaceutical Research at GSK, he played a role in growing the pipeline with antibodies, antibody fragments and recombinant protein therapeutics from concept to clinical development in a range of therapeutic areas. As VP, Head of Research, he played a major part in building the success of Domantis, a company focused on creating therapeutics using human domain antibodies and which was acquired by GSK in 2007. Neil has an Honorary Doctor of Science from Hertfordshire University. He holds a PhD in Biochemistry from Dundee University, Scotland.

Agenda Sessions

  • New Developments with Conditionally Activated Tetravalent Bispecific Antibodies